Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1195 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| mRNA-1195 Dose Level 1 (Low Dose) | EXPERIMENTAL | Participants will receive 3 intramuscular (IM) injections at dose level 1 (low dose) on a 0-, 2-, and 6-month schedule. |
| mRNA-1195 Dose Level 2 (High Dose) | EXPERIMENTAL | Participants will receive 3 IM injections at dose level 2 (high dose) on a 0-, 2-, and 6-month schedule. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive 3 placebo IM injections on a 0-, 2-, and 6-month schedule. |
| Name | Type | Description |
|---|---|---|
| mRNA-1195 | BIOLOGICAL | IM injection |
| Placebo | BIOLOGICAL | IM injection |
Inclusion Criteria: * Medically stable as determined by Investigator's medical evaluation, which will include assessment of medical history, physical examination, laboratory testing, and review of any previously conducted cardiac monitoring. * Participants who are Epstein-Barr virus (EBV)-seroposit...
mRNA-1195 is an investigational therapy being studied for relapse prevention in multiple sclerosis. It is currently in Phase 2 clinical development and is being evaluated in adults aged 18 to 55 years with the condition.
mRNA-1195 targets the Epstein-Barr virus (EBV), a virus implicated in multiple sclerosis. By targeting EBV, the therapy aims to address a potential underlying trigger of the disease.
mRNA-1195 is being developed by Moderna, Inc., a biotechnology company publicly traded under the ticker symbol MRNA on the Nasdaq stock exchange.
mRNA-1195 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being tested in clinical trials.
mRNA-1195 is being studied in a Phase 2 clinical trial with the identifier NCT06735248. The trial is recruiting participants with multiple sclerosis and is being conducted in the United States, Australia, and the United Kingdom.
mRNA-1195 is described as a monoclonal antibody modality, though its name suggests it may be an mRNA-based therapy. The clinical trial evaluates it against placebo in a randomized, double-blind design.